Key Highlights
- Hartmuth Kolb, PhD, appointed as Chief Science Officer (CSO) at Enigma Biomedical USA (EB).
- Brings over a decade of experience from Johnson & Johnson, focusing on Neuroscience Biomarkers and Imaging.
- Developed the first Tau-imaging PET biomarker, contributing significantly to neuroscience and precision medicine.
Source: Business Wire
Notable Quotes
- “Hartmuth is joining an already strong EB team in which, along with our recently appointed Chief Medical Officer, Dr. Samantha Budd- Haeberlein, we have deep expertise in drug and biomarker development for neurodegenerative disease and a catalyst to continue to achieve our Company’s mission and vision.” – Rick Hiatt, Chief Executive Officer at Enigma Biomedical USA
- “I am passionate about precision neuroscience, based on objective disease-related biomarkers, and am looking forward to joining the first-class Enigma team to develop new imaging biomarker solutions for diagnosis and staging of CNS disorders, which will enable the development of disease modifying therapies for patients.” – Hartmuth Kolb, PhD, Chief Science Officer at Enigma Biomedical USA
SoHC's Take
The appointment of Dr. Hartmuth Kolb as Chief Science Officer marks a significant milestone for Enigma Biomedical USA in its quest to pioneer the development of innovative biomarker solutions for the diagnosis and staging of CNS disorders. Dr. Kolb’s remarkable career, highlighted by his leadership in developing the first Tau-imaging PET biomarker, positions him as a key asset in advancing EB’s mission. His expertise, coupled with Enigma’s strategic focus on neuroimaging biomarkers, promises to significantly impact the future of neurodegenerative disease treatment, fostering the development of disease-modifying therapies. This move underscores EB’s commitment to enhancing brain health and the precision of neurological disease diagnosis, potentially setting new standards in the field.
